Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial

Publication | Closed Access

DOI

160

Citations

References

2008

Year

Nicholas D. James, Armelle Caty, Michael Borre, Bernard A. Zonnenberg, Philippe Beuzeboc, Thomas Morris, De Phung, Nancy A. Dawson

European Urology

UrologyOncologyHealth SciencesPain MedicineMedicineCancer PainPharmacotherapyPain ManagementHormone-resistant Prostate CancerPhase 2Prostatic DiseasePharmacologyPain Research